Novalgine I.M./I.V. (Metamizole Sodium Monohydrate)

Metamizole works by inhibiting cyclooxygenase enzymes, which reduces the production of prostaglandins that mediate pain and fever. It also has central nervous system effects that contribute to its analgesic and antipyretic properties, although the exact mechanism is not fully defined.

The appropriate dose of Novalgine I.M./I.V. is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data for metamizole in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Novalgine (metamizole) belongs to the pyrazolone class, offering strong analgesic and antipyretic effects similar to non‑opioid analgesics but with a distinct safety profile. Compared with NSAIDs, it has less gastrointestinal irritation but carries a risk of blood dyscrasias such as agranulocytosis.

Novalgine should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging. Do not freeze the solution. Follow the label instructions for handling to maintain sterility before administration.

Novalgine is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration should be performed by qualified healthcare personnel using aseptic technique, with the dose prepared according to the prescribing information.

The most serious risks include agranulocytosis, severe skin reactions such as Stevens‑Johnson syndrome, and anaphylaxis. Patients should be monitored for signs of infection, rash, or allergic reactions, and immediate medical attention is required if these occur.

Novalgine is contraindicated in patients with known hypersensitivity to metamizole or other pyrazolones, those with a history of agranulocytosis, and individuals receiving other myelosuppressive drugs. Caution is also advised in patients with severe renal or hepatic impairment.